News

COVID-19.info

Popularization of research advances on COVID-19

Treatments

An anti-protease treatment against SARS-CoV-2?

Although effective vaccines against COVID-19 are now on the market, there remains an urgent need to find drugs for the treatment of serious cases, since those currently available are limited. In addition, since other epidemics involving coronaviruses have occurred over the last twenty years (MERS-CoV, SARS-CoV-1), it is also important to develop active treatments against […]

Read more...

Use of the extracorporeal circulation technique

Hospital treatment of COVID-19 has changed significantly over the course of the pandemic. ECMO (Extracorporeal Membrane Oxygenation) is a form of cardio-respiratory support, also called extracorporeal circulation, which is proving beneficial. The system uses a machine that temporarily replaces the heart and the lungs in the blood circulation and oxygenation. Blood circulation is thereby diverted […]

Read more...

Reorganising research into new anti-COVID molecules

Since the start of the pandemic, biomedical research has made unprecedented efforts to improve patient health and halt the progression of SARS-CoV-2. The incredible levels of incidence of COVID-19 has facilitated the carrying out of enormous numbers of clinical trials to try and evaluate the effectiveness of new molecules and old (repositioning). However, few of […]

Read more...

A modified antibody that is more effective

Several neutralising antibodies that target SARS-CoV-2 have been developed and are undergoing clinical testing. Two anti-COVID-19 antibody cocktails are already on the market and reduce the risk of hospitalisation by 80%. However, these antibodies need to be administered in high doses, and their effectiveness remains limited. Researchers at the Universities of Rockefeller in New York […]

Read more...

The clinical benefits of anakinra

The health of COVID-19 patients can quickly degenerate. It is therefore crucial to be able to identify risks and treat them according to the clinical situation. When a case progresses towards the severe state, levels of suPAR (soluble urokinase plasminogen activator receptor) rise more rapidly and sooner than other known biomarkers of severity (CRP, IL-6, […]

Read more...

Masitinib: a new treatment against COVID-19?

When SARS-CoV-2 infects a cell, its genome enables the production of proteins that will be used to assemble new viral particles. The proteins are synthesised by the cellular machinery in the form of large polyproteins, cleaved by cellular and viral proteases. The viral proteases are a potentially useful target in the development of antiviral treatments […]

Read more...

Budesonide: inhalation treatment suitable for high-risk populations?

Effective and safe treatment against COVID-19 needs to be developed quickly, especially for elderly or high-risk individuals. Amongst medicines currently used, corticosteroids seem to reduce mortality rates in hospitalised patients, but in certain cases can have harmful side-effects and are not unanimously favoured by the medical community. They can be administered locally by inhalation, or […]

Read more...

Anticoagulants may be ineffective in severe cases

Severe cases of COVID-19 result in uncontrolled inflammation leading to thrombosis (formation of blood clots) in several organs. These risks are generally assessed by levels of specific circulating biomarkers, such as C-reactive protein or D-dimer. As a precaution, patients may be given preventative treatments based on heparin and low molecular weight derivatives (pharmacological thromboprophylaxis), in […]

Read more...

Tofacitinib: an effective drug against serious cases of COVID-19?

Tofacitinib is an oral medicine, initially used against auto-immune diseases such as rheumatoid arthritis, modulating immune system and inflammatory responses. In severe cases of COVID-19, the clinical symptoms are principally due to an immune response exacerbated by what we call a cytokinetic storm. Tofacitinib may improve levels of inflammation in patients. A study carried out […]

Read more...

Activating phospholipidosis to block SARS-CoV-2

 The urgency created by the pandemic and the absence of specific medicines meant that previously known molecules have been tried out as treatments. More than 1974 molecules have shown in vitro efficacy against SARS-CoV-2. Notably, those molecules targeting the sigma receptors (chloroquine, haloperidol, clemastine, PB28) modulate viral infection, but their mechanisms remain unknown. This figure […]

Read more...
error: Content is protected !!